Latest pharmaceutical drug prices and trends for NDC 66758-0252

Subscribe to access the full database, or Try for Free
Drug Name	NDC	Price/Unit ($)	Unit	Date
FOCALIN 10 MG TABLET	66758-0252-01	1.32810	EACH	2025-03-19
FOCALIN 10 MG TABLET	66758-0252-01	1.32834	EACH	2025-02-19
FOCALIN 10 MG TABLET	66758-0252-01	1.33013	EACH	2025-01-22
FOCALIN 10 MG TABLET	66758-0252-01	1.32804	EACH	2024-12-18
FOCALIN 10 MG TABLET	66758-0252-01	1.32954	EACH	2024-09-11
>Drug Name	>NDC	>Price/Unit ($)	>Unit	>Date

Subscribe to access the full database, or Try for Free

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies
Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
No data available in table
>Drug Name	>Vendor	>NDC	>Count	>Price ($)	>Price/Unit ($)	>Dates	>Price Type

In the ever-evolving landscape of pharmaceutical pricing, understanding market trends and projecting future costs is crucial for healthcare providers, payers, and patients alike. This comprehensive analysis delves into the market dynamics and price projections for the drug identified by National Drug Code (NDC) 66758-0252, offering insights that could shape strategic decisions in the healthcare industry.

Understanding NDC 66758-0252

Before we dive into the market analysis, it's essential to understand what NDC 66758-0252 represents. The National Drug Code is a unique, three-segment number assigned by the U.S. Food and Drug Administration (FDA) to human drugs in the United States. It serves as a universal product identifier for human drugs[9].

Product Identification

While the search results don't provide specific information about NDC 66758-0252, we can infer some details based on similar NDCs:

The labeler code "66758" is associated with Sandoz Inc.[5]
Sandoz Inc. is known for producing generic medications.
The specific drug associated with NDC 66758-0252 is likely a generic injectable medication, given Sandoz's product portfolio.

Current Pharmaceutical Market Trends

To project the future pricing of NDC 66758-0252, we must first understand the current market trends shaping the pharmaceutical industry.

Biologics and Biosimilars

The pharmaceutical market is experiencing a significant shift towards biologics and biosimilars. Biosimilars are expected to gain market share, potentially impacting the pricing of traditional small molecule drugs[7].

Digital Health and AI

Digital health technologies and artificial intelligence are revolutionizing patient support services and transforming healthcare interactions. This trend could indirectly affect drug pricing by improving efficiency and patient outcomes[7].

"Whether it's innovations in novel modalities and mechanisms of action (MOAs), breakthroughs in therapy areas with high unmet needs or changes to commercial strategies, most pharma pipelines and portfolios look much different today than they did as recently as a couple of years ago." - ZS Insights[7]

Gross-to-Net Erosion

Increased gross-to-net erosion is a significant challenge for pharmaceutical manufacturers. This trend refers to the widening gap between a drug's list price and the manufacturer's net revenue after accounting for various deductions[7].

Price Projection Factors for NDC 66758-0252

Several factors will likely influence the future pricing of NDC 66758-0252:

Market Demand

The demand for the specific drug associated with NDC 66758-0252 will play a crucial role in its pricing. If it's a widely used medication with stable or increasing demand, we might expect modest price increases[4].

Production Costs

Any changes in production costs, such as raw material prices or manufacturing overheads, could lead to price adjustments. Global supply chain dynamics can significantly impact these costs[4].

Regulatory Environment

Changes in regulatory policies, particularly those related to price transparency and affordability, could influence pricing strategies. Programs like Oregon's Drug Price Transparency Program may affect how manufacturers set and report prices[4].

Potential Price Increase Scenarios

Based on current trends and factors, we can project two potential scenarios for NDC 66758-0252:

Moderate Increase

If market conditions remain stable and there are no significant changes in production costs or the regulatory environment, we might expect a moderate price increase of around 5-10%[4].

Higher Increase

In the event of a surge in demand or significant increases in production costs, the price could increase more substantially, potentially up to 15-20%. This scenario is plausible given the historical volatility in generic drug pricing[4].

Industry-Wide Price Projections

To put our projections for NDC 66758-0252 into context, let's look at industry-wide price projections:

Vizient, Inc. projects drug price inflation to grow at 3.8% in the latest Pharmacy Market Outlook. Driven in part by specialty pharmacy, including the increasing utilization of weight loss drugs, it is the highest projected increase since July 2019[8].

This projection suggests that our moderate increase scenario for NDC 66758-0252 aligns with broader industry trends.

Impact of Generic Competition on Pricing

Generic competition plays a crucial role in determining drug prices. According to a study by the U.S. Department of Health and Human Services:

"Prices continue to decline by 70% to 80% relative to the pre-generic entry price in markets of 10 or more competitors following 3 years after generic entry." - ASPE Issue Brief[8]

This finding suggests that if NDC 66758-0252 faces increased generic competition, we could see significant price reductions over time.

Technological Advancements in Pharmaceutical R&D

Technological advancements, particularly in AI and data analytics, are reshaping the pharmaceutical industry's approach to research and development. This trend could have indirect effects on pricing:

AI-Driven Drug Discovery

AI is accelerating drug discovery processes, potentially reducing the time and cost associated with bringing new drugs to market. For example:

Amgen has doubled its clinical trial enrollment speed using a multimodal, data-driven machine learning tool[7].
BMS is using AI and machine learning to advance protein degradation science[7].

These advancements could lead to more efficient drug development processes, potentially offsetting some of the upward pressure on prices.

Patient-Centric Clinical Trials

The industry is moving towards more patient-centric clinical trials, which could improve trial efficiency and reduce costs:

Sanofi is collaborating with OpenAI and Formation Bio to develop an AI tool that reduces patient recruitment timelines "from months to minutes"[7].

This focus on efficiency could help control R&D costs, which may have a stabilizing effect on drug prices.

Supply Chain Optimization and Resilience

The pharmaceutical industry is increasingly focusing on supply chain optimization and resilience, which could impact pricing strategies:

Smart Manufacturing

90% of biopharma executives surveyed by ZS said they are investing in smart manufacturing to increase supply chain efficiency[7]. Companies like Amgen and Roche are leading examples of this trend.

Domestic Manufacturing

Proposed legislation and geopolitical concerns are driving companies to strengthen their domestic manufacturing capabilities:

"We'll be prepared to address any political changes that occur in Washington, D.C., to protect the continuity of our supply," - Executive at a large pharma company[7]

These investments in supply chain resilience could lead to more stable pricing in the long term, but may also result in short-term cost increases as companies adapt.

Evolving Portfolio Strategies

Pharmaceutical companies are evolving their portfolio strategies, which could influence the pricing of individual drugs like NDC 66758-0252:

Focus on High Unmet Needs

Drugmakers are increasingly shifting focus to therapy areas (TAs) that are broadly perceived to have high unmet needs. About half of the 10 largest pharma companies are focusing on TAs beyond core areas such as oncology and immunology[7].

"Always Be Launching" Mindset

To reduce reliance on blockbusters and sustain revenue in a challenging environment, some companies are adopting an "always be launching" mindset. For example, GSK expects to launch 12 new treatments in 2025[7].

These strategic shifts could lead to more diverse product portfolios, potentially affecting pricing strategies across different drug categories.

Regulatory and Policy Landscape

The regulatory and policy landscape plays a significant role in shaping pharmaceutical pricing:

Price Transparency Initiatives

Programs like Oregon's Drug Price Transparency Program require manufacturers to report price increases, which could influence pricing decisions[4].

Affordability Reviews

Some states are implementing affordability review boards that can conduct reviews of drug prices, potentially impacting pricing strategies[4].

Federal Policy Changes

The outcome of the 2024 U.S. presidential election and potential changes in healthcare policy could significantly impact drug pricing regulations and market dynamics.

Future Outlook for NDC 66758-0252

As we look towards 2025 and beyond, several factors will continue to shape the pharmaceutical market and potentially impact the pricing of NDC 66758-0252:

Technological Advancements

Continued advancements in drug development and manufacturing technologies could lead to more efficient production processes, potentially offsetting some of the upward pressure on prices.

Policy Changes